Q&A with Dr Gary Waanders Director of Healthcare Research at Zeus Capital
17th February 2017
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
Falanx Group’s Jay Abbott discusses how things are progressing at their new office in Birmingham, the prototyping of new technology, his thoughts on the government’s £20 million investment in cyber security education for kids, why Falanx is different and potential new contract wins in this exclusive interview with DirectorsTalk
KEFI Minerals’ Harry Anagnostaras-Adams discusses the strategy underlying their latest announcement, the major new shareholder, the deal with Lanstead, the main milestones and the share consolidation in this exclusive interview with DirectorsTalk
Ascent Resources’ Colin Hutchinson discusses the successful fundraising of £3 million via PrimaryBid, whether they’re on track to bring gas to market in the near future and plans to settle the loan notes in this exclusive interview with DirectorsTalk
Georgian Mining Corp’s Greg Kuenzel discusses the significant drill intercepts at the Kvemo Bolnisi project, what the next steps are and what investors should be looking out for in this exclusive interview with DirectorsTalk
Zeus Capital’s Dr Gary Waanders dsicusses Oncimmune Holdings PLC in this exclusive interview with DirectorsTalk
Powerhouse Energy Group PLC (LON:PHE) Chief Executive Officer Keith Allaun caught up with DirectorsTalk for an exclusive interview to discuss the appointment of Waste2Tricity as Project Development Consultant, the G3
Hardman & Co Analyst Mark Thomas caught up with DirectorsTalk for an exclusive interview to discuss Morses Club PLC (LON:MCL) Q1: Now Mark, Morses Club, a home collect credit
Proteome Sciences plc (LON:PRM) Chief Executive Officer Jeremy Haigh caught up with DirectorsTalk for an exclusive interview to discuss the latest trading update, the consolidation of their Frankfurt laboratory, the
Versarien’s Neill Ricketts discusses their new graphene brand ’Nanene’, what it is & what it’ll be used for, their focus on the graphene area and the challenges of being at the forefront of graphene commercialization in this exclusive interview with DirectorsTalk
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
